æImportant information

•Always prime your Innovo® (as described on page 10 -11) to ensure the insulin flow:

•before each injection

•after changing Penfill®

•after changing the needle

•after opening and closing the slide

•With a Penfill® in Innovo®, never press the push button unless

a needle is mounted.

•Always make sure that the push button is pressed completely in and locks.

The display confirms completed delivery when the segments turn on two by two and then the circle appears.

•Do not change the dose after you have pressed the push button.

•On the Penfill® label there is a coloured band that is unique to the different types of insulin. When

Penfill® is inserted into Innovo®, the coloured band is visible through the slide. Before each injection make sure that you are using the right type of insulin.

•If you are treated with more than one type of insulin in Penfill® 3 ml cartridges, you should use two devices, one for each type of insulin.

•Do not use the residual scale to measure the amount of insulin to be injected.

•Take the needle off Innovo® immediately after each injection.

If you do not remove it, temperature changes may cause liquid to leak out of the needle. With an insulin suspension (cloudy insulin), this may change the concentration of the insulin.

•Do not initiate injection of an insulin suspension (cloudy insulin) if the rubber stopper is below the arrow marks on the slide.

32

Page 35 Page 37
Page 36
Image 36
Novo Nordisk 510620 manual ÆImportant information
Page 35 Page 37

510620 specifications

Novo Nordisk 510620 is a cutting-edge medication developed by the renowned healthcare company Novo Nordisk, which specializes in diabetes care and other chronic diseases. As a part of Novo Nordisk's innovative product portfolio, 510620 is particularly aimed at addressing the needs of patients with type 2 diabetes, a condition that affects millions worldwide.

One of the main features of Novo Nordisk 510620 is its formulation as a GLP-1 receptor agonist. GLP-1, or glucagon-like peptide-1, is a hormone that plays a crucial role in glucose metabolism. By mimicking the action of this hormone, 510620 stimulates insulin secretion in response to meals, inhibits glucagon release, and promotes satiety. This multi-faceted approach not only helps in lowering blood sugar levels but also aids in weight management, making it particularly suitable for overweight individuals with type 2 diabetes.

In terms of technology, Novo Nordisk 510620 utilizes a novel delivery system that enhances the bioavailability and stability of the active ingredient. This innovative technology involves an injectable formulation that is designed for easy administration, with pre-filled pens that allow patients to self-inject the medication comfortably. The convenience of the delivery system assists in improving patient adherence to treatment protocols, an essential factor in managing chronic conditions such as diabetes.

Another characteristic of Novo Nordisk 510620 is its cardiovascular benefits. Clinical studies have shown that patients using this medication not only achieve better glycemic control but also experience a reduction in the risk of major cardiovascular events. This attribute is critical, considering the high prevalence of cardiovascular complications associated with diabetes.

Safety and tolerability are also key aspects of Novo Nordisk 510620. The medication has undergone rigorous clinical trials, which have demonstrated a favorable safety profile, with common side effects being mild to moderate. Regular monitoring and education about potential side effects play a vital role in ensuring that patients can use 510620 effectively.

In summary, Novo Nordisk 510620 represents an advanced treatment option for type 2 diabetes, characterized by its GLP-1 receptor agonist activity, innovative delivery technology, cardiovascular benefits, and strong safety profile. By continually working on research and development, Novo Nordisk aims to improve the quality of life for individuals affected by chronic diseases, making substantial contributions to the field of diabetes management.
Top Page Image Contents